Adriana Carr Selected Research

G(M3) Ganglioside

6/2019	Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.
1/2015	Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.
1/2014	Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer.
1/2013	Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin.
1/2013	Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis.
1/2012	Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer.
1/2011	Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms.
1/2011	Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adriana Carr Research Topics

Disease

11	Neoplasms (Cancer) 11/2020 - 12/2002
5	Melanoma (Melanoma, Malignant) 06/2013 - 04/2008
4	Breast Neoplasms (Breast Cancer) 01/2011 - 03/2003
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2015 - 01/2012
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 06/2019
1	Prostatic Neoplasms (Prostate Cancer) 01/2019
1	Carcinoma (Carcinomatosis) 01/2017
1	Colonic Neoplasms (Colon Cancer) 01/2014
1	Lymphoma (Lymphomas) 01/2013
1	Lymphatic Metastasis 01/2013
1	Skin Neoplasms (Skin Cancer) 01/2011
1	Arthralgia (Joint Pain) 09/2010
1	Injection Site Reaction 09/2010
1	Neoplasm Metastasis (Metastasis) 09/2010
1	Fever (Fevers) 09/2010
1	Chills 09/2010
1	Meningococcal Meningitis 04/2008
1	Vitiligo 04/2008
1	Breast Ductal Carcinoma 03/2003

Drug/Important Bio-Agent (IBA)

9	GangliosidesIBA 06/2013 - 03/2003
8	G(M3) GangliosideIBA 06/2019 - 01/2011
6	VaccinesIBA 01/2019 - 03/2003
5	Biological ProductsIBA 06/2019 - 09/2010
3	AntigensIBA 01/2013 - 04/2008
3	Immunoglobulin G (IgG)IBA 01/2013 - 12/2002
3	Monoclonal AntibodiesIBA 01/2011 - 12/2002
3	Cancer VaccinesIBA 09/2010 - 03/2003
2	Epidermal Growth Factor (EGF)IBA 01/2017 - 01/2015
2	montanide ISA 51IBA 09/2010 - 04/2008
1	PolyphenolsIBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 11/2020
1	nimotuzumabIBA 11/2020
1	ParaffinIBA 06/2019
1	Formaldehyde (Formol)FDA Link 06/2019
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2019
1	Testosterone (Sustanon)FDA Link 01/2019
1	AntibodiesIBA 01/2019
1	Amino Acids FDA Link 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	N-glycolylneuraminic acidIBA 01/2013
1	GlycoconjugatesIBA 01/2013
1	Heterophile AntigensIBA 01/2013
1	proteoliposomesIBA 01/2012
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 07/2008
1	Tyr sulfate(1)- enkephalinamide-Leu (LETS)IBA 07/2008
1	Complement System Proteins (Complement)IBA 03/2003

Therapy/Procedure

6	Immunotherapy 01/2013 - 03/2003
3	Therapeutics 01/2019 - 07/2008
2	Drug Therapy (Chemotherapy) 06/2013 - 12/2002
1	Radioimmunotherapy 11/2020
1	Subcutaneous Injections 01/2012
1	Intramuscular Injections 03/2003